Skip to main content
Premium Trial:

Request an Annual Quote

XDx Inks PGx Collaboration with Bristol-Myers for Lupus

NEW YORK (GenomeWeb News) – XDx said today that it has signed a pharmacogenomics pact with Bristol-Myers Squibb to identify biomarkers that would be used for diagnostic purposes in the development of a drug for systemic lupus erythematosus.
XDx is developing non-invasive, gene-expression tests for monitoring immune-mediated conditions. Bristol-Myers will make an upfront payment to XDx and additional milestone payments based on the achievement of specific R&D objectives. Brisbane, Calif.-based XDx also gets commercial rights to certain diagnostic applications that result from the collaboration.
The firms will be working on tests to monitor the effectiveness of Bristol-Myers’ rheumatoid arthritis drug abatacept (Orencia) in treating lupus.
Further terms of the collaboration were not disclosed.

Filed under

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.